EMA, US FDA Worry About AI’s Pitfalls And Promises

 
• By Derrick Gingery

The “garbage in, garbage out” issue remains top of mind as AI models continue to be integrated into drug development. The FDA still has a lot of learning to do, Jacqueline Corrigan-Curay says.

AI and human hand
Could AI exacerbate clinical trial diversity concerns? • Source: Shutterstock

US and European officials have big plans for artificial intelligence, including use in application review and safety signal identification, but both regulators remain concerned about the software’s limitations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Advanced Technologies